Leukotoxin Selective Leukocyte Targeting Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for inflammatory disorders and HIV infection are often ineffective or associated with significant side effects, and there is a need for novel therapeutic agents that can specifically target activated leukocytes involved in these conditions.

Innovation Solution

Leukotoxin (LtxA) from Aggregatibacter actinomycetemcomitans is used to selectively target and kill white blood cells expressing activated LFA-1, both for treating inflammatory disorders and reducing HIV-infected cells, with minimal toxicity to other cells or organs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for inflammatory disorders are used, then therapeutic effect is achieved, but significant side effects occur

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent utilizes leukotoxin, a harmful bacterial toxin that normally kills white blood cells, and converts it into a beneficial therapeutic agent by selectively targeting and eliminating pathologically activated leukocytes in inflammatory disorders like Crohn's disease, thereby treating the disease while minimizing damage to healthy cells

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The invention applies local quality by making the treatment selectively act on specific cell types (activated leukocytes expressing LFA-1) rather than affecting all cells uniformly. The leukotoxin is designed to specifically bind to and kill only those leukocytes that are pathologically activated, leaving normal cells unaffected

Inventive Principle:

Principle #3Local quality

2Reliability

If current treatments for HIV infection are used, then viral replication is suppressed, but treatment duration is prolonged and side effects increase

Engineering Contradiction:

Improveviral suppressionVSAvoidtreatment duration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent converts the harmful leukotoxin into a beneficial tool for HIV treatment by using it to selectively eliminate HIV-infected cells that express activated LFA-1, thereby shortening antiretroviral therapy duration and reducing cumulative side effects while maintaining viral suppression

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Object-affected harmful factors

If broad-spectrum immunosuppressants are used, then inflammatory symptoms are reduced, but immune system function is compromised

Engineering Contradiction:

Improveinflammatory symptomsVSAvoidimmune system function

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The invention applies local quality by selectively targeting only pathologically activated leukocytes for elimination while preserving the function of normal immune cells. This localized approach reduces inflammatory symptoms without compromising overall immune system function, unlike broad-spectrum immunosuppressants

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

LtxA effectively treats inflammatory disorders like psoriasis and reduces HIV-infected cells by specifically targeting activated leukocytes, offering a targeted therapy with reduced side effects and potential to shorten antiretroviral therapy duration.

Implementation Method 1

Leukotoxin (LtxA) from Aggregatibacter actinomycetemcomitans is used to selectively target and kill white blood cells expressing activated LFA-1

Methodology Applied

Scientific EffectCytotoxicity through pore formation:

Data Source

PatentUS11612636B2Method of treating autoimmune inflammatory crohn's disease

Publication Date: 2023.03.28 RUTGERS THE STATE UNIV

AI summary

This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.